Danoprevir

Ascletis Announces Cooperation with China Meheco International Co., Ltd. in Distribution of Its Ritonavir Tablets in Chinese Mainland

Retrieved on: 
Wednesday, April 13, 2022

HANGZHOU, China and SHAOXING, China, April 13, 2022 /PRNewswire/ --Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Ascletis Pharmaceuticals Co., Ltd. ("Ascletis Pharmaceuticals") has signed an agreement with China Meheco International Co., Ltd. for distribution of its ritonavir tablets in Chinese mainland.

Key Points: 
  • HANGZHOU, China and SHAOXING, China, April 13, 2022 /PRNewswire/ --Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Ascletis Pharmaceuticals Co., Ltd. ("Ascletis Pharmaceuticals") has signed an agreement with China Meheco International Co., Ltd. for distribution of its ritonavir tablets in Chinese mainland.
  • Ascletis Pharmaceuticals is a wholly-owned subsidiary of Ascletis, and China Meheco International Co., Ltd. is a wholly-owned subsidiary of China Meheco Group Co., Ltd. ("China Meheco").
  • By this opportunity, we hope to explore various levels of cooperation with biotech companies in China such as Ascletis.
  • Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis, said, "It's a great honor to cooperate with China Meheco in commercialization of ritonavir tablets.

Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy

Retrieved on: 
Friday, December 3, 2021

HANGZHOU, China and SHAOXING, China, Dec. 2, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that its all-oral direct anti-hepatitis C virus (HCV) ASCLEVIR® (Ravidasvir)/ GANOVO® (Danoprevir) regimen has been included in the Medicine Catalog for National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021) (《国家基本医疗保险、工伤保险和生育保险药品目录(2021)年》) (the "National Reimbursement Drug List" or the "NRDL"). 

Key Points: 
  • The results from the Phase II/III clinical trials in China with the all-oral direct anti-HCV ASCLEVIR / GANOVO regimen showed a 99% cure rate in genotype 1 non-cirrhosis HCV patients.
  • ASCLEVIR is a pan-genotypic NS5Ainhibitor with high genetic barrier to resistance, with a cure rate of 100% in patients with baseline NS5Aresistance.
  • "The assessment by National Healthcare Security Administration ("NHSA") is based on multi-factors including efficacy, safety, economy, novelty and fairness.
  • Ascletis will continue to support the country's healthcare system and contributes to the national 'Healthy China' strategy."

Array BioPharma to Present at the 39th Annual Cowen Health Care Conference

Retrieved on: 
Tuesday, March 5, 2019

Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases.

Key Points: 
  • Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases.
  • Vitrakvi (larotrectinib, partnered with Bayer AG) is approved in the United States and Ganovo (danoprevir, partnered with Roche) is approved in China.
  • For more information on Array, please visit www.arraybiopharma.com or follow @arraybiopharma on Twitter and LinkedIn.
  • BRAFTOVI and MEKTOVI are registered trademarks of Array BioPharma Inc. in the United States and various other countries.

Ascletis' Ganovo is Eligible for Shaoxing Government Funding Subsidy Program to Treat HCV Patients

Retrieved on: 
Monday, October 15, 2018

HANGZHOU, Chinaand SHAOXING, China, Oct. 15, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) announced today Ganovo (Danoprevir) is the only direct-acting anti-viral agent (DAA) eligible for Shaoxing government funding subsidy, according to Shaoxing's Action Plan to Accelerate Prevention and Treatment of Hepatitis C ("Plan") issued recently.

Key Points: 
  • HANGZHOU, Chinaand SHAOXING, China, Oct. 15, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) announced today Ganovo (Danoprevir) is the only direct-acting anti-viral agent (DAA) eligible for Shaoxing government funding subsidy, according to Shaoxing's Action Plan to Accelerate Prevention and Treatment of Hepatitis C ("Plan") issued recently.
  • The Plan defines that 70% of the DAA expenses will be reimbursed by local government for the HCV patients who are Shaoxing residents and treated at the designated hospitals.
  • This is another important milestone for patient access to Ganovo after its recent enrollment in Tianjin Basic Medical Insurance Program under capped-reimbursement per patient pilot program.
  • "We are optimistic that more HCV patients will be treated timely and HCV prevention and treatment work in China will move up quickly to the new level due to government efforts to treat HCV patients."